HOME >> BIOLOGY >> NEWS
Enzyme Required To Prolong Life In Worms Identified By Researchers At Columbia; Key Enzyme Appears To Protect Animal Cells From Oxidative Damage

Researchers at Columbia University have discovered an enzyme that is required to prolong the life span of microscopic roundworms and that strains of long-lived worms appear to produce in greater quantity than normal.

They believe the enzyme, called cytosolic catalase, protects cells from oxidative damage, considered a key element in the aging process in all animals, including humans. Because oxidative damage has been implicated in Alzheimer's and Lou Gehrig's disease, the work may prompt medical researchers to ask new questions about such nervous system diseases.

"Our work demonstrates that oxidative damage is an important determinant of life span, and control of such damage might affect the life span of other organisms," said Martin Chalfie, professor of biological sciences at Columbia and leader of the team that produced the research, which is described in the May 13 issue of the British journal Nature.

The research was carried out in Caenorhabditis elegans, a soil worm about 1/25 of an inch long that is a common experimental animal. The tiny worm has been useful to aging research because its normal three-week life span can be extended by environmental factors. In situations of overcrowding, food shortages or both, the emerging worm goes into a dormant period that can last as long as two months. If food is provided within that time, the animal emerges from dormancy and goes on to live its normal three weeks.

Scientists studying a possible genetic component to life span have been fascinated by this extended larval phase, called the dauer stage. "Dauer" means "lasting" in German. Several scientific teams have found mutations that send the worm into the dauer state at elevated temperatures. But even at normal temperatures and without going into the dauer stage, these mutant adults live two to four times longer than non-mutants. Yet these same mutants, if also bred to lack cytosolic catalase, died af
'"/>

Contact: Bob Nelson, Office of Public Affairs
rjn2@columbia.edu
212-854-6580
Columbia University
12-May-1999


Page: 1 2 3 4

Related biology news :

1. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
2. Enzyme activation appears key in helping internal clock tell night from day
3. Enzyme fully degrades mad cow disease prion
4. Enzyme revealed that is key to funguss ability to breach immune system
5. Enzyme discovery sheds light on causes of rare disease, cancer
6. Enzyme could overcome industrial bleaching waste problems
7. Enzyme controls good cholesterol
8. Enzyme discovery to benefit homeland security, industry
9. Enzyme could aid cancer fight
10. Enzyme once thought harmful to Alzheimers patients now appears key to future treatment
11. Enzyme mimetic reduces tissue damage in colitis animal study

Post Your Comments:
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
(Date:7/29/2015)... Station, TX (PRWEB) , ... July 29, 2015 ... ... POD® designer, manufacturer and supplier, announces the launch of their 2nd generation cell ... to the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
(Date:7/29/2015)...  Indivior PLC (LON: INDV) today announced that the ... accepted and received Priority Review by the U.S. Food ... overdose. This naloxone nasal spray comes as a pre-filled ... into the nasal mucosa. 1 The device has ... be better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
Cached News: